Leveraging
Our Expertise

Gilead is researching new treatments to help address the needs of people living with inflammatory and fibrotic diseases, including primary biliary cholangitis (PBC), inflammatory bowel disease, lupus and metabolic dysfunction-associated steatohepatitis (MASH).

Leveraging our network of partnerships and extensive expertise in immunology, we're advancing a range of programs to help address these chronic conditions and the toll they take on patients’ lives.

Leveraging-Our-ExpertiseLeveraging-Our-Expertise-Mobile

Advancing Options for Primary Biliary Cholangitis

PBC is a rare, chronic, autoimmune disease that primarily affects women and can cause liver damage and possible liver failure if left untreated. The disease currently has no cure. More than half of people diagnosed with the condition are asymptomatic, but the symptoms that commonly appear — such as pruritus, or chronic skin itching — are often invisible to others, debilitating and can severely affect health-related quality of life. The journey to a PBC diagnosis can be long and challenging, especially when for many, there are no signs of the disease that others can see.

There has been a lack of new and effective treatment options for PBC until recently, with nothing available that addresses both the symptoms of PBC, as well as disease progression. We are constantly striving to improve liver care and provide more options so patients don’t have to settle for a treatment that may not address symptoms that severely impact their health-related quality of life.

Inflammation-Woman-Paddles-Kayak-Across-LakeInflammation-Woman-Paddles-Kayak-Across-Lake
Area-Of-Focus-BGArea-Of-Focus-BG-Mobile
Areas of Focus
Rheumatology

Rheumatology

Pulmonology

Pulmonology

Dermatology

Dermatology

Hepatology

Hepatology

Gastroenterology

Gastroenterology

Blocking-Immune-Activation
Blocking immune activation
Eliminating-Pathogenic-Cells
Eliminating pathogenic cells
Tolerizing-Immune-Response
Tolerizing immune response
Restoring-Function
Restoring function & promoting regeneration
Clinical-Trial

Clinical Trials

We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.

Inflammation-Cards-Medicines

Medicines

We currently offer more than 25 therapies in the United States and are rapidly growing our portfolio through internal research and development and external collaborations.

Latest News

Some of the content on this page is not intended for users outside the U.S.